bioRxivMicrobiology
Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion H69/V70
S. Kemp, B. Meng, I. Ferreira, R. Datir, W. Harvey, D. Collier, COVID-19 Genomics UK (COG-UK) consortium, G. Papa, A. Carabelii, S. Lytras, J. Kenyon, A. Lever, L. James, D. L. Robertson, R. K. Gupta
Abstract
SARS-CoV-2 amino acid replacements in the receptor binding domain (RBD) occur relatively frequently and some have a consequence for immune recognition. Here we report recurrent emergence and significant onward transmission of a six-nucleotide out of frame deletion in the S gene, which results in loss of two amino acids: H69 and V70. We report that in human infections {Delta}H69/V70 often co-occurs with the receptor binding motif amino acid replacements N501Y, N439K and Y453F, and in the latter two cases has followed the RBD mutation. One of the {Delta}H69/V70+ N501Y lineages, now known as B.1.1.7, has undergone rapid expansion and includes eight S gene mutations: RBD (N501Y and A570D), S1 ({Delta}H69/V70 and {Delta}144) and S2 (P681H, T716I, S982A and D1118H). In vitro, we show that {Delta}H69/V70 does not reduce serum neutralisation across multiple convalescent sera. However, {Delta}H69/V70 increases infectivity and is associated with increased incorporation of cleaved spike into virions. {Delta}H69/V70 is able to compensate for small infectivity defects induced by RBD mutations N501Y, N439K and Y453F. In addition, replacement of H69 and V70 residues in the B.1.1.7 spike reduces its infectivity and spike mediated cell-cell fusion. Based on our data {Delta}H69/V70 likely acts as a permissive mutation that allows acquisition of otherwise deleterious immune escape mutations. Enhanced surveillance for the {Delta}H69/V70 deletion with and without RBD mutations should be considered as a global priority not only as a marker for the B.1.1.7 variant, but potentially also for other emerging variants of concern. Vaccines designed to target the deleted spike protein could mitigate against its emergence as increased selective forces from immunity and vaccines increase globally. HighlightsO_LI{Delta}H69/V70 is present in at least 28 SARS-CoV-2 lineages C_LIO_LI{Delta}H69/V70 does not confer escape from convalescent sera C_LIO_LI{Delta}H69/V70 increases spike infectivity and compensates for RBD mutations C_LIO_LI{Delta}H69/V70 is associated with greater spike cleavage C_LIO_LIB.1.1.7 requires {Delta}H69/V70 for optimal spike cleavage and infectivity C_LI
- organism: human
- assay: whole-genome sequencing
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein
Marco Gerdol, Klevia Dishnica, Alejandro Giorgetti·Virus ResearchPeer-reviewed·Jan 10, 2022
- B.1.617.3 SARS CoV-2 spike E156G/Δ157-158 mutations contribute to reduced neutralization sensitivity and increased infectivity
- Mutations of SARS-CoV-2 variants of concern escaping Spike-specific T cells
N. Le Bert, A. T. Tan, … A. Bertoletti·bioRxiv·Jan 20, 2022
- Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants
M. McCallum, A. C. Walls, … D. Veesler·bioRxiv·Aug 11, 2021
- Effects of common mutations in the SARS-CoV-2 Spike RBD domain and its ligand the human ACE2 receptor on binding affinity and kinetics
M. I. Barton, S. MacGowan, … P. A. van der Merwe·bioRxiv·May 18, 2021
- A virus that has gone viral: Amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding and thus infectivity
P. Saha, A. K. Banerjee, … U. Ray·Bioscience ReportsPeer-reviewed·May 15, 2020